Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis

Value in Health

Volumn 7, Issue 5, 2004, Pages 554-568

  Prosser, Lisa A ^a   Kuntz, Karen M ^b   Bar Or, Amit ^c   Weinstein, Milton C ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD CENTER FOR RISK ANALYSIS   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Beta interferon; Cost effectiveness; Glatiramer acetate; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ANALYTIC METHOD; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE COURSE; DRUG COST; DRUG SCREENING; EVALUATION; FEMALE; HEALTH; HUMAN; HYPOTHESIS; IMMUNOMODULATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MODEL; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; RELAPSE; SIDE EFFECT; SOCIAL ASPECT; STANDARD;

EID: 6344228360     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.75007.x     Document Type: Article

References (52)

1. Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993;13:333-40.
2. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25.
3. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-61.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
5. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-63.
6. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
7. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76.
8. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
10. Ebers GC, Koopman WJ, Hader W, et al. The natural history of multiple sclerosis: a geographically based study. 8. Familial multiple sclerosis. Brain 2000;123:641-9.
11. Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol 1998;18:301-7.
12. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989;46:1107-12.
13. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46.
14. Runmarker B, Anderson O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34.
15. Goodkin DS. The Northern California MS Study Group. Survey of multiple sclerosis in northern California. Mult Scler 1999;5:78-88.
16. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State multiple sclerosis consortium. Mult Scler 1999;5:369-76.
17. Miller DH, Hornabrook RW, Purdie G. The natural history of multiple sclerosis: a regional study with some longitudinal data. J Neurol Neurosurg Psych 1992;55:341-6.
18. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28.
19. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-61.
20. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in northeast Scotland. J Neurol, Neurosurg Psychiatry 1998;50:523-31.
21. Anderson RN. United States Life Tables, 1998. National Vital Statistics Reports, Vol. 48 No. 18. Hyattsville, Maryland: National Center for Health Statistics, 2001.
22. Mohr DC, Likosky W, Boudewyn AC, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with Interferon beta-1a. Mult Scler 1998;4:487-9.
23. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996;46:552-4.
24. Logan-Clubb L, Stacy M. An open-labeled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis. J Neurosci Nurs 1995;27:344-7.
25. Weinstock-Guttman B, Cohen JA. Newer versus older treatments for relapsing-remitting multiple sclerosis. Drug Saf 1996;14:121-30.
26. Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996;2:222-6.
27. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-18.
28. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 2003;9:311-19.
29. US Department of Commerce, Bureau of Economic Analysis. Available from: http://www.bea.doc.gov/bea/newsrel/gdp499p.htm. [Last accessed Mar 3, 2000].
30. Drug Topics Red Book. Montvale, NJ: Medical Economics Co., Inc., 1999.
31. Bureau of Labor Statistics. Available from: http://stats.bls.gov/news. release/wkyeng.nws.htm. [Last accessed Mar 9, 2000].
32. 1999 Medicare Clinical Laboratory Fee Schedule. Available from: http://www.cms.hhs.gov/providers/pufdownload/clfdown.asp. [Last accessed March 3, 2000].
33. 1999 National Physician Fee Schedule Relative Value File. Available from: http://cms.hhs.gov/providers/pufdownload/rvudown.asp. [Last accessed Mar 3, 2000].
34. Stolp-Smith KA, Atkinson EJ, Campion ME, et al. Health care utilization in multiple sclerosis. A population-based study in Olmsted County, MN. Neurology 1998;50:1594-600.
35. Fishman P, Von Korff M, Lozano P, Hecht J. Chronic care costs in managed care. Health Aff 1997;16:239-47.
36. Inman RP. The economic consequences of debilitating illness: the case of multiple sclerosis. Rev Econ Stat 1987;69:651-60.
37. Bourdette DN, Prochazka AV, Mitchell W, et al. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. Arch Phys Med Rehabil 1993;74:26-31.
38. Brown MG, Murray TJ, Fisk JD, et al. A Therapeutic and Economic Assessment of Betaseron in Multiple Sclerosis. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1996. Technology report.
39. Brown MG, Murray TJ, Sketris IS, et al. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis progression: first estimates. IJTAHC 2000;16:751-67.
40. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 1998;2:1-66.
41. Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999;319:1529-33.
42. Kendrick M, Johnson KI. Long term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics 2000;18:45-53.
43. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003;326:522-6.
44. Kobelt G, Jonsson L, Henriksson F, et al. Cost-utility analysis of interferon beta-lb in secondary progressive multiple sclerosis. Int J Tech Assess Health Care 2000;16:768-80.
45. Kobelt G, Jonsson L, Miltenburger C, et al. Cost-utility analysis of interferon beta-lb in secondary progressive multiple sclerosis using natural history data. Int J Tech Assess Health Care 2002;18:127-38.
46. Kobelt G, Jonsson L, Fredrikson S. Cost-utility of interferon beta-lb in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econom 2003;4:50-9.
47. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-56.
48. Sadovnick AD, Eisen RN, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193-6.
49. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-9.
50. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
51. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002;51:481-90.
52. Comi G, Filippi M, Barkhof F, et al. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82.